Included in the formulation
АТХ:A.07.X.A.04 Racecadotril
Pharmacodynamics:Inhibits enkephalinase, enhances action endogenous enkephalins. This reduces the secretory activity of the intestine, without affecting the peristalsis. Does not affect the central nervous system. Do not cumulate.
Pharmacokinetics:After ingestion, up to 90% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 1 hour.
Therapeutic effect develops after 30 minutes after taking and continues for 8 hours. Metabolism in the liver to the active metabolite (RS) -N-oxo-2- (mercaptomethyl) -3-phenylpropyl) glycine, which is subsequently transformed into inactive metabolites.
The elimination half-life is 3-4 hours. Elimination of kidneys and feces in the form of inactive metabolites.
Indications:It is used for the treatment of infectious and non-infectious diarrhea.
I.A00-A09.A09 Diarrhea and gastroenteritis of allegedly infectious origin
XI.K55-K63.K59.1 Functional diarrhea
Contraindications:Severe hepatic and renal insufficiency, age to 18 years, individual intolerance.
Carefully:
Pregnancy and lactation, hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category B. Applicable with caution, in cases where the expected effect exceeds the risk to the fetus and newborn.
Dosing and Administration:Inside, 100 mg 3 times a day.
The highest daily dose: 400 mg.
The highest single dose: 100 mg.
Side effects:Central and peripheral nervous system: dizziness, drowsiness.
Respiratory system: rarely - tonsillitis.
Digestive system: nausea, vomiting, constipation.
Dermatological reactions: a rash, erythema.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:When taking the drug is not recommended driving and working with moving machinery.